Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC

Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.

Leave a comment

Your email address will not be published. Required fields are marked *